ISSN: 2381-8727

炎症、がん、統合療法に関する国際ジャーナル

オープンアクセス

当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Profiles of Endoglinand Vascular Endothelial Growth Factor-Based on Staging and Histological Grading of Colorectal Cancer, and Its Relationship with Bevacizumab Therapy Cancer

Rahmawati Minhajat

ABSTRACT: This study evaluated the profile of CD105 (Endoglin) and VEGF protein based on staging

and histopathological grading of Colorectal Cancer, and evaluated its relationship with

bevacizumab therapy. A total of 88 cases of colorectal adenocarcinoma were included in this study.

The levels of VEGF and CD105 were evaluated with ELISA. There was a significant difference in

CD105 protein level (p=0.002) between metastases and non-metastases subjects, where CD105

level is higher in metastatic colorectal adenocarcinoma (4.59ng/ml). There was no significant

difference of VEGF protein level based on the presence of metastasis (p=0.625); however, VEGF

levels tended to be higher in subjects with metastases (650.27pg/ml). There was a significant

difference of CD105 (p=0.038) and VEGF level (p=0.010) between the subjects who received

chemotherapy and those did not. The CD105 level was found higher in the subjects who received

chemotherapy (4.43ng/ml); otherwise VEGF level was found lower in subjects who received

chemotherapy (543.65pg/ml). There were a significant difference of CD105 level (p=0.003) and

VEGF levels (p=0.002) between subjects who received bevacizumab therapy and subjects who did

The levels of CD105 protein were higher in subjects who received bevacizumab therapy

(5.11ng/ml), in contrast, VEGF level was higher in subjects who did not receive bevacizumab

(645.92pg/ml). There was a significant positive correlation between CD105 and VEGF in subjects

who did not receive bevacizumab (p<0.01); in contrast, there was no significant correlation between

CD105 and VEGF levels in subjects who received bevacizumab (p>0.05). The results of this study

support a hypothesis of "escape mechanism" in the failure of anti-angiogenesis therapy (anti

VEGF).